Indication assessment · §3
Metabolic dysfunction-associated steatohepatitis — trial records
Trial records in the Institute's register bearing on metabolic dysfunction-associated steatohepatitis.
§3Trials in this indication
22 trial records in the Institute's register bear on this indication, of which 5 are published trials.
Table 2. Trial records bearing on metabolic dysfunction-associated steatohepatitis.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| ESSENCE | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 1,197 | 2025 |
| SURVO-PH2-MASH | Survodutide | Phase 2 | Randomised, double-blind, placebo-controlled | 295 | 2024 |
| SYNERGY-NASH | Tirzepatide | Phase 2 | Randomised, double-blind, placebo-controlled | 190 | 2024 |
| LIVERAGE | Liraglutide | Phase 2 | Randomised, double-blind, placebo-controlled | 52 | 2016 |
| TESA-NAFLD-PH2 | Tesamorelin | Phase 2 | Randomised, double-blind, placebo-controlled | 61 | 2019 |
| ESSENCE-PKprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2025 |
| SURVO-PH2-MASH-PKprogramme record | Survodutide | Phase 1 | Phase 1 ascending dose | — | 2024 |
| SYNERGY-NASH-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2024 |
| LIVERAGE-BIOMARKERprogramme record | Liraglutide | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2016 |
| TESA-NAFLD-PH2-PKprogramme record | Tesamorelin | Phase 1 | Phase 1 ascending dose | — | 2019 |
| ESSENCE-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2025 |
| SURVO-PH2-MASH-RENAL-IMPprogramme record | Survodutide | Phase 1 | Phase 1 ascending dose | — | 2024 |
| SYNERGY-NASH-QOLprogramme record | Tirzepatide | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2024 |
| LIVERAGE-ADHERENCEprogramme record | Liraglutide | Phase 2 | Observational | — | 2016 |
| TESA-NAFLD-PH2-RENAL-IMPprogramme record | Tesamorelin | Phase 1 | Phase 1 ascending dose | — | 2019 |
| SYNERGY-NASH-BODY-COMPprogramme record | Tirzepatide | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2024 |
| LIVERAGE-OLEprogramme record | Liraglutide | Phase 2 | Single-arm open-label | — | 2016 |
| TESA-NAFLD-PH2-HEPATIC-IMPprogramme record | Tesamorelin | Phase 1 | Phase 1 ascending dose | — | 2019 |
| ESSENCE-DDIprogramme record | Semaglutide | Phase 1 | Randomised crossover | — | 2025 |
| LIVERAGE-ELDERLYprogramme record | Liraglutide | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2016 |
| LIVERAGE-RENAL-IMPprogramme record | Liraglutide | Phase 1 | Phase 1 ascending dose | — | 2016 |
| TESA-NAFLD-PH2-BODY-COMPprogramme record | Tesamorelin | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2019 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-05/3 · https://compoundevidence.com/indications/mash/trials/ · retrieved 30 July 2026